Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants (Q24245418)

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Erythropoietin concentrations and neurodevelopmental outcome in preterm infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

An approach to using recombinant erythropoietin for neuroprotection in very preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

The Effect of Recombinant Human Erythropoietin on Circulating Hematopoietic Progenitor Cells in Anemic Premature Infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Recombinant erythropoietin and blood transfusion in selected preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Follow-up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Effects of a combined therapy of erythropoietin, iron, folate, and vitamin B12 on the transfusion requirements of extremely low birth weight infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

High-versus low-dose erythropoietin in extremely low birth weight infants. The European Multicenter rhEPO Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Erythropoietin in the neonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Effect of beginning recombinant erythropoietin treatment within the first week of life, among very-low-birth-weight neonates, on "early" and "late" erythrocyte transfusions: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Reducing blood donor exposures in low birth weight infants by the use of older, unwashed packed red blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Changing practices of red blood cell transfusions in infants with birth weights less than 1000 g.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Erythropoietin as a retinal angiogenic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

The use of erythropoietin in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Erythropoietin treatment in extremely low birth weight infants: blood in versus blood out.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Current issues in neonatal transfusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Changing patterns of red blood cell transfusion in very low birth weight infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

Preventive effect of different dosage of recombinant human erythropoietin on anemia of premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Blood transfusion. Iron load and retinopathy of prematurity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Prediction of the need for transfusion during anemia of prematurity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Postnatal changes in erythropoietin levels in untransfused premature infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: A randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Anemia of prematurity. Current concepts in the issue of when to transfuse.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Effect of recombinant human erythropoietin on transfusion needs in preterm infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Meta-analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

The effect of early recombinant erythropoietin and enteral iron supplementation on blood transfusion in preterm infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Recombinant human erythropoietin therapy in low-birthweight preterm infants: a prospective controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Effect of recombinant human erythropoietin in preterm infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Anemia of prematurity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Use of erythropoietin and its effects on blood lactate and 2, 3-diphosphoglycerate in premature neonates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Efficacy and safety of recombinant human erythropoietin to prevent the anaemias of prematurity. European Randomized Multicenter Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Erythropoietin therapy for premature infants: cost without benefit?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021

Comparison between two and five doses a week of recombinant human erythropoietin for anemia of prematurity: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004863.PUB2

7 January 2021